Authors
Latest:
Trends in coding audits and what physicians can expectRecent trends in medical audits and what physicians can expect with the CMS changes in 2021 to the documentation of E/M codes.
Latest:
FDA grants breakthrough device designation for ArteraAI Prostate tool“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
Latest:
Enhancing Patient-Centric Management in OAB in 2024 and BeyondPanelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.
Latest:
Christine Ibilibor, MD, highlights study of racial differences in abiraterone useData showed that African American men faced significant delays in treatment initiation.
Latest:
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Lymph nodes in bladder cancer: Past, present, and future"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.
Latest:
Bridget Lang Findlay, MD, discusses patient-centered bladder management in SCI careFindlay advocated for comprehensive patient counseling that includes the full range of BMS options, not just those available within a provider’s immediate practice.
Latest:
Ruchika Talwar, MD, on how urologists can get involved in advocacy“I always encourage urologists and physicians in general to keep up with the organizations that they're a part of, like the AUA, that often advocate on your behalf," says Ruchika Talwar, MD.
Latest:
UT Money Matters: Are REITs right for your portfolio?Real estate investment trusts (REITs) offer an alternative asset to stocks or bonds that provide a convenient way to get income from rental properties without the risks and commitment of owning directly.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
Emulating target trials using observational evidence to inform clinical decision-making"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Latest:
AUA 2024: Key Takeaways & Future of NMIBC ManagementGary D. Steinberg, MD, summarizes his major takeaway from the AUA 2024 conference and shares his insights on the potentially practice-changing developments he anticipates in the near future for the management of non-muscle-invasive bladder cancer (NMIBC).
Latest:
Prostate cancer survivor treated at MUSC shares his storyProstate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.
Latest:
Advice for limiting malpractice insurance costsExpert advice for physicians seeking new coverage.
Latest:
Kidney stone treatment inches toward precision medicine"As more genes are classified and catalogued, diagnosis and treatment of kidney stones inches further and further toward 'precision medicine,' " write Rutul Patel, DO, MS, and Alexander Small, MD.
Latest:
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC“I think the big take-home message is now we've got multiple, multiple drugs showing that we can do significantly better than ADT alone," says Fred Saad, MD, FRCS.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
Unsolved Mystery: Where did COVID-19 come from?Questions remain surrounding the origin of the global pandemic.
Latest:
ADT Treatment Considerations and Unmet Needs in Prostate CancerExperts on prostate cancer discuss current unmet needs in the therapeutic landscape and outline treatment considerations for patients receiving androgen deprivation therapy.
Latest:
Study shows gender disparities in CKD detection and treatment“We observed profound differences in the detection work up and management of chronic kidney disease suggesting suboptimal care among women,” said Juan Jesus Carrero, PharmD, PhD.
Latest:
Bladder Cancer Advocacy Network (BCAN) announces $600,000 in funding to accelerate breakthroughs in bladder cancer researchAwardees are being recognized for creative approaches to accelerating progress in bladder cancer research.
Latest:
Expert Forum: Fertility after exogenous testosterone replacementTreatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.
Latest:
GNRH agonists vs antagonists in prostate cancer: How to chooseMany factors play into decision-making process when weighing agents.
Latest:
Andrew C. Peterson, MD, MPH, on counseling men regarding the artificial urinary sphincter"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH.
Latest:
Malpractice Consult: How attorneys successfully cross-examine expert witnesses"Effective cross-examination can create an implication that an expert’s opinions are motivated by bias or self-interest, rather than a neutral evaluation of the facts. This is frequently accomplished by highlighting the fact that experts are paid for time spent reviewing a case and testifying," writes Kenton H. Steele, Esq.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
